Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 6
1994 4
1995 2
1996 3
1997 2
1998 23
1999 33
2000 47
2001 53
2002 84
2003 83
2004 102
2005 102
2006 104
2007 121
2008 102
2009 103
2010 118
2011 116
2012 93
2013 104
2014 109
2015 122
2016 96
2017 111
2018 97
2019 96
2020 110
2021 121
2022 110
2023 117
2024 49

Text availability

Article attribute

Article type

Publication date

Search Results

2,329 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.
Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Marucci G, et al. Neuropharmacology. 2021 Jun 1;190:108352. doi: 10.1016/j.neuropharm.2020.108352. Epub 2020 Oct 6. Neuropharmacology. 2021. PMID: 33035532 Free article. Review.
The ChE-Is currently available in the market are donepezil, rivastigmine and galantamine as tacrine is no longer in use, due to its hepatotoxicity. According to mechanism of action the ChE-Is are classified as short-acting or reversible agents such as tacrine, donepezil, a …
The ChE-Is currently available in the market are donepezil, rivastigmine and galantamine as tacrine is no longer in use, due to its h …
Cholinesterase inhibitors for Alzheimer's disease.
Birks J. Birks J. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD005593. doi: 10.1002/14651858.CD005593. Cochrane Database Syst Rev. 2006. PMID: 16437532 Free PMC article. Review.
OBJECTIVES: To assess the effects of donepezil, galantamine and rivastigmine in people with mild, moderate or severe dementia due to Alzheimer's disease. ...There appears to be less adverse effects associated with donepezil compared with rivastigmine. It may be that …
OBJECTIVES: To assess the effects of donepezil, galantamine and rivastigmine in people with mild, moderate or severe dementia due to …
Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline.
Howell M, Avidan AY, Foldvary-Schaefer N, Malkani RG, During EH, Roland JP, McCarter SJ, Zak RS, Carandang G, Kazmi U, Ramar K. Howell M, et al. J Clin Sleep Med. 2023 Apr 1;19(4):759-768. doi: 10.5664/jcsm.10424. J Clin Sleep Med. 2023. PMID: 36515157 Free PMC article. Review.
(CONDITIONAL). 4. The AASM suggests that clinicians use transdermal rivastigmine (vs no treatment) for the treatment of isolated RBD in adults with mild cognitive impairment. ...(CONDITIONAL). 7. The AASM suggests that clinicians use transdermal rivastigmine (vs no …
(CONDITIONAL). 4. The AASM suggests that clinicians use transdermal rivastigmine (vs no treatment) for the treatment of isolated RBD …
Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis.
d'Angremont E, Begemann MJH, van Laar T, Sommer IEC. d'Angremont E, et al. JAMA Neurol. 2023 Aug 1;80(8):813-823. doi: 10.1001/jamaneurol.2023.1835. JAMA Neurol. 2023. PMID: 37358841
STUDY SELECTION: Studies were selected if they presented the results of placebo-controlled randomized clinical trials, including at least 1 donepezil, rivastigmine, or galantamine treatment arm in patients with AD, PD, or DLB; if they applied at least 1 neuropsychiatric me …
STUDY SELECTION: Studies were selected if they presented the results of placebo-controlled randomized clinical trials, including at least 1 …
Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis.
Veroniki AA, Ashoor HM, Rios P, Seitidis G, Stewart L, Clarke M, Tudur-Smith C, Mavridis D, Hemmelgarn BR, Holroyd-Leduc J, Straus SE, Tricco AC. Veroniki AA, et al. BMJ Open. 2022 Apr 26;12(4):e053012. doi: 10.1136/bmjopen-2021-053012. BMJ Open. 2022. PMID: 35473731 Free PMC article.
For moderate-to-severe impairment, donepezil, memantine and their combination performed best, but for mild-to-moderate impairment donepezil and transdermal rivastigmine ranked best. Adjusting for MMSE baseline differences, oral rivastigmine and galantamine improved …
For moderate-to-severe impairment, donepezil, memantine and their combination performed best, but for mild-to-moderate impairment donepezil …
Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
Battle CE, Abdul-Rahim AH, Shenkin SD, Hewitt J, Quinn TJ. Battle CE, et al. Cochrane Database Syst Rev. 2021 Feb 22;2(2):CD013306. doi: 10.1002/14651858.CD013306.pub2. Cochrane Database Syst Rev. 2021. PMID: 33704781 Free PMC article.
Three cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) are licenced for the treatment of dementia due to Alzheimer's disease. ...Three trials studied donepezil 5 mg or 10 mg daily (n= 2193); three trials studied rivastigmine at a maximum daily do …
Three cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) are licenced for the treatment of dementia due to Alzheime …
The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.
Fan F, Liu H, Shi X, Ai Y, Liu Q, Cheng Y. Fan F, et al. J Alzheimers Dis. 2022;85(3):1195-1204. doi: 10.3233/JAD-215423. J Alzheimers Dis. 2022. PMID: 34924395
The results showed that AChE inhibitors (donepezil, galantamine, rivastigmine, Huperzine A), Ginkgo biloba, and cerebrolysin appear to be beneficial for cognitive, global performances, and activities of daily living in patients with AD. ...
The results showed that AChE inhibitors (donepezil, galantamine, rivastigmine, Huperzine A), Ginkgo biloba, and cerebrolysin appear t …
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Hansen RA, et al. Clin Interv Aging. 2008;3(2):211-25. Clin Interv Aging. 2008. PMID: 18686744 Free PMC article. Review.
Three open-label trials and one double-blind randomized trial directly compared donepezil with galantamine and rivastigmine. Results are conflicting; two studies suggest no differences in efficacy between compared drugs, while one study found donepezil to be more efficacio …
Three open-label trials and one double-blind randomized trial directly compared donepezil with galantamine and rivastigmine. Results …
Acetylcholinesterase inhibitors for autistic spectrum disorders.
Ure A, Cox GR, Haslam R, Williams K. Ure A, et al. Cochrane Database Syst Rev. 2023 Jun 1;6(6):CD013851. doi: 10.1002/14651858.CD013851.pub2. Cochrane Database Syst Rev. 2023. PMID: 37267443 Review.
Low levels of acetylcholine have been investigated as a potential contributor to autism symptomatology. Donepezil, galantamine, and rivastigmine (commonly referred to as acetylcholinesterase inhibitors) all inhibit acetylcholinesterase, and have slightly different modes of …
Low levels of acetylcholine have been investigated as a potential contributor to autism symptomatology. Donepezil, galantamine, and rivas …
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
Parsons C, Lim WY, Loy C, McGuinness B, Passmore P, Ward SA, Hughes C. Parsons C, et al. Cochrane Database Syst Rev. 2021 Feb 3;2(2):CD009081. doi: 10.1002/14651858.CD009081.pub2. Cochrane Database Syst Rev. 2021. PMID: 35608903 Free PMC article. Review.
Two classes of drug - cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and memantine - are widely licensed for dementia due to Alzheimer's disease, and rivastigmine is also licensed for Parkinson's disease dementia. ...
Two classes of drug - cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and memantine - are widely licensed for dem …
2,329 results